by Gregory T. Bleck, PhD
Volume 5, Issue 4 (Winter 2006)
Biopharmaceutical companies are constantly evaluating new methods for mammalian cell line development that provide benefits such as shorter timelines, improved consistency, higher production, better genetic stability, and increased flexibility. Each of these advantages extends a large cost benefit to companies as their recombinant protein products are moved from development into the clinic and finally to commercial launch. A versatile system has been developed that is capable of transferring genes of interest into a wide variety of mammalian host cells and offers a number of the above advantages over other methods. The system, which is referred to as GPEx™ (an acronym for “gene product expression”), utilizes replication-defective retroviral vectors, derived from Moloney murine leukemia virus (MLV) and pseudotyped with vesicular stomatitis virus G protein (VSV-G), to stably insert single copies of genes into dividing cells…
Citation:
Bleck GT. An Alternative Method for the Rapid Generation of Stable, High-Expressing Mammalian Cell Lines. BioProcess J, 2006; 5(4): 36-42. https://doi.org/10.12665/J54.Bleck